Tezspire is currently approved for the treatment of severe asthma in the US, EU, Japan, and nearly 60 countries across the globe. It is approved as a single-use pre-filled syringe and auto-injector ...

AstraZeneca and Daiichi Sankyo have changed up their approval plans for a closely watched lung cancer medicine, a decision ...

AstraZeneca is set to report its third-quarter 2024 earnings Tuesday morning. The company's Q2 performance suggests strong ...

The companies did not provide detailed data for Tezspire, however, and William Blair’s Matt Phipps said in a note he does not ...

Fiera Capital Corp trimmed its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 5.9% during the third quarter, according to the company in its most recent filing with the Securities and ...

Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Receive News & Ratings for ...

That includes a £25m profit hit in the current financial year, which will also be impacted by reduced expectations for sale ...

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

Amgen and AstraZeneca said on Friday that their asthma drug Tezspire reduced nasal congestion and the size of nasal polyps in patients with a different but sometimes related inflammatory condition ...

Results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps showed that AstraZeneca (AZN) and ...